重组促红细胞生成素管理中的持续质量改进（CQI）：结果
Continuous quality improvement (CQI) in rhu-Epo management: the outcome.
作者信息
Descamps C, Van Waeleghem J P, Ysebaert D
机构信息
Nephrology Unit, University Hospital, Antwerp.
出版信息
EDTNA ERCA J. 1996 Jul-Sep;22(3):22-6.
PMID:10723328
Abstract
The establishment of an adequate recombinant erythropoietin (epo) treatment for haemodialysis patients has challenged nephrology workers for the last 5 years. Starting with epo, it was quickly clear that its management was complex and a lot of conditions were involved in its effective application.
摘要
在过去5年里，为血液透析患者建立适当的重组促红细胞生成素（epo）治疗方法一直是肾脏病学工作者面临的挑战。从促红细胞生成素开始，很快就清楚其管理很复杂，并且其有效应用涉及很多条件。
Zotero 插件